TPG Biotech

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in developing radiopharmaceuticals as precision medicines. It focuses on creating targeted alpha therapeutics using its proprietary linker technology to enhance the safety and efficacy of these drugs, ultimately improving cancer patient outcomes.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Engage Therapeutics, Inc. is a biopharmaceutical company based in Summit, New Jersey, focused on developing innovative therapies for individuals experiencing uncontrolled epileptic seizures. Its lead investigational product, Staccato alprazolam, is a small, handheld drug-device combination designed for the rapid cessation of active and acute seizures. Utilizing an FDA-approved delivery system, the Staccato device administers alprazolam, an established benzodiazepine, in a single inhalation. The product has shown promise in a Phase 2a proof of concept study, which indicated potential reductions in seizures within a photosensitivity model. Engage Therapeutics is advancing Staccato alprazolam through clinical development, employing a 505(b)(2) regulatory pathway to facilitate its market entry.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in developing radiopharmaceuticals as precision medicines. It focuses on creating targeted alpha therapeutics using its proprietary linker technology to enhance the safety and efficacy of these drugs, ultimately improving cancer patient outcomes.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Progyny is a fertility benefits management company that designs and administers comprehensive family-building benefits for employers in the United States. Its solution combines plan design, personalized member support, and a selective network of high-quality fertility clinics and specialists to guide patients through treatment, along with Progyny Rx, an integrated pharmacy benefits component. The company also covers surrogacy and adoption expenses as part of its offerings. By coordinating education, access to advanced fertility services, and cost management, Progyny aims to improve clinical outcomes while reducing employer healthcare expenses.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in developing radiopharmaceuticals as precision medicines. It focuses on creating targeted alpha therapeutics using its proprietary linker technology to enhance the safety and efficacy of these drugs, ultimately improving cancer patient outcomes.

Adynxx is a biopharmaceutical company established in San Francisco, California, in 2007. It specializes in developing innovative drugs for pain management. The company's primary focus is on creating novel therapeutics called transcription factor decoys to address unmet needs in treating pain and inflammation. Adynxx has two key drug candidates: brivoligide, currently in Phase 2 trials for postoperative pain prevention, and AYX2, a preclinical candidate targeting chronic inflammatory and neuropathic pain syndromes. Additionally, the company offers other therapeutic programs aimed at providing long-term relief for mature chronic pain syndromes.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Progyny is a fertility benefits management company that designs and administers comprehensive family-building benefits for employers in the United States. Its solution combines plan design, personalized member support, and a selective network of high-quality fertility clinics and specialists to guide patients through treatment, along with Progyny Rx, an integrated pharmacy benefits component. The company also covers surrogacy and adoption expenses as part of its offerings. By coordinating education, access to advanced fertility services, and cost management, Progyny aims to improve clinical outcomes while reducing employer healthcare expenses.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing proprietary, late-stage products that address non-medical use and abuse of prescription drugs through tamper-resistant formulations and extended-release delivery using its patent-protected DETERx platform. The company markets Xtampza ER, an abuse-deterrent extended-release oxycodone, and Nucynta products, including extended-release and immediate-release formulations of tapentadol for long- and short-term pain management. Its portfolio also includes Jornay as part of its product lineup, reflecting a strategy to expand applications of the DETERx technology. Headquartered in Stoughton, Massachusetts.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

8990 Holdings develops and sells residential properties in the Philippines, focusing on affordable housing projects. It operates through four segments: Low-Cost Mass Housing, Medium-Rise Condominiums, High-Rise Condominiums, and Others. The company also engages in hotel operations and rental of investment properties.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

GoHealth Urgent Care is a healthcare provider that focuses on delivering accessible and high-quality urgent care services. With locations across New York, Oregon, Washington, California, and Connecticut, the company aims to enhance the patient experience through a welcoming environment and efficient service. GoHealth integrates with leading health systems and maintains a broad network of physicians and clinicians, allowing it to offer comprehensive emergency care. The organization is committed to making urgent health services affordable and convenient for patients, with plans for further expansion into new markets.

PatientSafe Solutions, headquartered in San Diego, California, specializes in smart point-of-care mobile solutions aimed at transforming healthcare delivery. Its flagship product, the PatientTouch System, enhances care team productivity and patient safety by consolidating clinical workflows into a single, portable device. The innovative platform integrates communication, workflow management, and real-time access to electronic medical records, facilitating effective collaboration among clinicians. Features such as Positive Patient Identification, customizable care interventions, and real-time alerting capabilities support critical processes like medication administration and specimen collection. By leveraging advanced technology, PatientSafe Solutions enables healthcare providers to improve safety, increase efficiency, and reduce operational costs, positioning itself as a leader in accountable care innovation.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.

Veracyte is a global genomic diagnostics company that improves patient care by providing genomic tests to inform diagnosis and treatment decisions. Its portfolio includes tests for thyroid, lung, breast cancer, idiopathic pulmonary fibrosis, and prostate cancer, with more in development.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

ChemEOR, Inc. specializes in the development and supply of customized chemical products for the oil and natural gas production industry on a global scale. Founded in 2005 and headquartered in Covina, California, the company produces surfactants, polymers, gels, and specialty products that enhance well stimulation, reservoir recovery, and flow assurance in various applications, including mature fields, shale development, and deepwater projects. ChemEOR's innovative approach employs molecular design methods to create cost-effective and environmentally friendly formulations, aimed at increasing oil production rates and improving recovery from aging fields. The company operates production and distribution facilities in Houston, Los Angeles, Denver, and Midland, contributing to enhanced energy access while striving to minimize environmental impact.

Alphabet Energy, Inc. is a company that specializes in waste heat recovery technology, transforming waste heat into electricity. Founded in 2009 and headquartered in Hayward, California, with an additional office in Houston, Texas, the company offers a range of products, including power generating combustors, thermoelectric devices, and exhaust heat recovery generators designed for various applications. Their innovative thermoelectric approach, developed from research at the Lawrence Berkeley National Laboratory, allows for large-scale production at low cost using sustainable materials. Alphabet Energy's solutions cater to diverse industries such as automotive, oil and gas, manufacturing, and defense, enabling customers to enhance fuel efficiency and generate electrical power from waste heat sources.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Tandem Diabetes Care is a medical device company that designs, manufactures, and markets insulin pumps and related diabetes management solutions. Founded in 2006 and headquartered in San Diego, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a compact pump, a 300‑unit disposable cartridge, and an infusion set. The system is available with Basal‑IQ, Control‑IQ, and G5 integration features, and can be updated through the Tandem Device Updater. Tandem also offers the t:connect web application for data visualization and the Sugarmate mobile app for insulin‑using patients. In development are the t:sport pump, the Mobi and Tobi tubeless pumps, and the Sigi patch pump. The company partners with Dexcom for integrated glucose monitoring and sells its products primarily in the United States, with a growing presence in other developed markets.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Alphabet Energy, Inc. is a company that specializes in waste heat recovery technology, transforming waste heat into electricity. Founded in 2009 and headquartered in Hayward, California, with an additional office in Houston, Texas, the company offers a range of products, including power generating combustors, thermoelectric devices, and exhaust heat recovery generators designed for various applications. Their innovative thermoelectric approach, developed from research at the Lawrence Berkeley National Laboratory, allows for large-scale production at low cost using sustainable materials. Alphabet Energy's solutions cater to diverse industries such as automotive, oil and gas, manufacturing, and defense, enabling customers to enhance fuel efficiency and generate electrical power from waste heat sources.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, focusing on serious genetic conditions with limited treatment options. The company leverages its team's experience to create life-changing medicines by advancing underdeveloped scientific research in these areas.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

Elevance Renewable Sciences, Inc. specializes in producing and distributing specialty chemicals derived from natural plant oils through a process known as oil metathesis. Founded in 2007 and headquartered in Woodridge, Illinois, the company develops a diverse range of products, including cleaning ingredients, coating materials, personal care components, and chemical intermediates for various industries such as agriculture, pharmaceuticals, and polymers. Elevance's offerings cater to applications in detergents, coatings, and engineered polymers, among others. In addition to its product lines, the company provides manufacturing consulting, engineering, and technical consulting services focused on bio-based feedstocks and intermediates. By transforming renewable oils into high-performance specialty products, Elevance is positioned to address consumer demand in a growing market.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.

Veracyte is a global genomic diagnostics company that improves patient care by providing genomic tests to inform diagnosis and treatment decisions. Its portfolio includes tests for thyroid, lung, breast cancer, idiopathic pulmonary fibrosis, and prostate cancer, with more in development.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

Tandem Diabetes Care is a medical device company that designs, manufactures, and markets insulin pumps and related diabetes management solutions. Founded in 2006 and headquartered in San Diego, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a compact pump, a 300‑unit disposable cartridge, and an infusion set. The system is available with Basal‑IQ, Control‑IQ, and G5 integration features, and can be updated through the Tandem Device Updater. Tandem also offers the t:connect web application for data visualization and the Sugarmate mobile app for insulin‑using patients. In development are the t:sport pump, the Mobi and Tobi tubeless pumps, and the Sigi patch pump. The company partners with Dexcom for integrated glucose monitoring and sells its products primarily in the United States, with a growing presence in other developed markets.

Draths Corporation is a pioneering chemical company dedicated to producing biobased materials for various applications, including nylons, plastics, paints, and resins. By leveraging proprietary technologies that combine metabolic engineering, synthetic biology, and chemical synthesis, the company transforms renewable feedstocks into primary chemical ingredients. Its product offerings include shikimic acid, aminoshikimic acid, quinic acid, butanetriol, phloroglucinol, caprolactam, vanillin, myo-inositol, dehydroshikimic acid, gallic acid, pyrogallol, and tetrahydroxybenzene. Draths focuses on environmentally friendly processes that significantly reduce carbon footprints while maintaining cost-effectiveness, thereby providing sustainable alternatives to traditional petroleum-based chemicals used in everyday products.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

ProteoGenix specializes in developing and commercializing diagnostic testing products for maternal-fetal health. Its portfolio includes non-invasive tests for detecting intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and Down syndrome.

Tandem Diabetes Care is a medical device company that designs, manufactures, and markets insulin pumps and related diabetes management solutions. Founded in 2006 and headquartered in San Diego, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a compact pump, a 300‑unit disposable cartridge, and an infusion set. The system is available with Basal‑IQ, Control‑IQ, and G5 integration features, and can be updated through the Tandem Device Updater. Tandem also offers the t:connect web application for data visualization and the Sugarmate mobile app for insulin‑using patients. In development are the t:sport pump, the Mobi and Tobi tubeless pumps, and the Sigi patch pump. The company partners with Dexcom for integrated glucose monitoring and sells its products primarily in the United States, with a growing presence in other developed markets.

moksha8 Pharmaceuticals, Inc. is a prominent pharmaceutical company based in Berwyn, Pennsylvania, focused on licensing, marketing, and distributing therapeutics in Brazil and Mexico. Established in 2006, the company provides a range of treatments for various medical conditions, including central nervous system disorders, oncology, cardiology, rheumatology, endocrinology, and respiratory issues. Moksha8 has formed strategic alliances with notable partners such as Biopas Laboratories, Roche, Pfizer, BioCryst, and Watson, enhancing its presence and capabilities in the Latin American market.

JCR Pharmaceuticals is a Japan-based company engaged in the pharmaceutical sector, focusing on the research, production, and sale of medical drugs and pharmaceutical raw materials. The company is particularly active in developing enzymes and proteins to create innovative treatment options for unmet medical needs. In addition to its core pharmaceutical business, JCR Pharmaceuticals also operates in the medical and research equipment market, which includes the purchase and sale of related devices. The company leverages international partnerships as part of its growth strategy, with a significant portion of its revenue generated from pharmaceutical operations, complemented by income from medical devices and licensing agreements.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.